Real-World Experience of the Efficacy and Safety of Upadacitinib 15 mg in Patients with Atopic Dermatitis in Korea
- Author:
Hyoung Min NA
1
;
Eun Ji CHOI
;
Soo Hyun JEON
;
Zhong Fan CHANG
;
Myoung Eun CHOI
;
Ik Jun MOON
;
Joon Min JUNG
;
Woo Jin LEE
;
Sung Eun CHANG
;
Mi Woo LEE
;
Chong Hyun WON
Author Information
1. Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2023;61(2):86-91
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Upadacitinib is an oral Janus kinase1 (JAK1)-selective inhibitor, which showed a quick and significant effect on patients with atopic dermatitis in several phase 3 clinical studies. Although, an increasing number of studies have reported data on the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis, no studies have yet been published in Korea.
Objective:We assessed the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis in Korean patients.
Methods:A total of 17 patients with atopic dermatitis who received 15 mg of oral upadacitinib everyday for 16 weeks, were included in this retrospective single-center study. Based on electronic medical records, the clinical characteristics, Eczema Area and Severity Index (EASI) score, and adverse events were investigated.
Results:The mean EASI score was significantly reduced at 4 weeks of upadacitinib treatment (8.81±9.00) and gradually reduced at week 8 (5.70±7.38), week 12 (4.55±6.23), and week 16 (4.58±6.74) (p＜0.001). At week 16, 61.54%, 30.77%, and 15.38% of patients achieved EASI 75, EASI 90, and EASI 100 responses, respectively. There was no statistically significant difference between EASI 75 and EASI 90 by age or gender at week 16 (p＞0.05). A total of 13 people (76.5%) had adverse events, of which acne was the most common. In all patients, the symptoms were mild and self-limited, and no patient discontinued treatment.
Conclusion:Upadacitinib was effective and safe for Korean patients with atopic dermatitis in real-world clinical practice.
